AOMS1
MCID: ABD014
MIFTS: 64

Abdominal Obesity-Metabolic Syndrome 1 (AOMS1)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 56 12 15
Metabolic Syndrome X 56 12 74 29 54 71
Metabolic Syndrome 43 62 39 17
Abdominal Obesity Metabolic Syndrome 71
Dysmetabolic Syndrome X 12
Metabolic Disease 17
Aoms1 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:14221
OMIM 56 605552
OMIM Phenotypic Series 56 PS605552
ICD9CM 34 277.7
MeSH 43 D024821
NCIt 49 C84442
SNOMED-CT 67 237602007
MedGen 41 C4552048
UMLS 71 C0524620 C2930930

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 56 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to acquired metabolic disease and abdominal obesity-metabolic syndrome quantitative trait locus 2, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Topiramate and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and heart, and related phenotypes are hypertension and abdominal obesity

Disease Ontology : 12 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events.

PubMed Health : 62 About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke. The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease. In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries. Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 74 Metabolic syndrome is a clustering of at least three of the five following medical conditions: abdominal... more...

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3 Abdominal Obesity-Metabolic Syndrome 4

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2200)
# Related Disease Score Top Affiliating Genes
1 acquired metabolic disease 32.6 SLC2A4 SERPINE1 RETN PPARG PPARA NOS3
2 abdominal obesity-metabolic syndrome quantitative trait locus 2 32.3 SLC2A4 SERPINE1 RETN PPARG PPARD PPARA
3 hyperlipidemia, familial combined, 3 32.3 PPARA LPL INS ADIPOQ
4 platelet glycoprotein iv deficiency 32.3 PPARG PPARA LPL INS
5 fatty liver disease 32.2 RETN PPARG PPARA MTTP MIR122 LEP
6 prediabetes syndrome 32.0 SLC2A4 PPARG PPARA LEP INS GCG
7 non-alcoholic fatty liver disease 31.4 SLC2A4 SERPINE1 RETN PPARG PPARA MTTP
8 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.3 LEP INS ADIPOQ
9 liver disease 31.3 RETN PPARA MIR122 MEG3 LEP INS
10 pellagra 31.2 PPARG INS ADIPOQ
11 abetalipoproteinemia 31.2 MTTP LPL LEP
12 fatty liver disease, nonalcoholic 1 31.2 RETN PPARA MTTP LEP INS ADIPOQ
13 glycogen storage disease ia 31.1 LPL INS GCG
14 arteries, anomalies of 30.9 SERPINE1 PPARG NOS3 MIR33A MIR122 LEP
15 hyperandrogenism 30.9 PPARG INS IGFBP1 HSD11B1 ADIPOQ
16 endocrine system disease 30.9 MIR33A LEP INS GCG
17 acanthosis nigricans 30.8 SLC2A4 PPARG LEP INS ADIPOQ
18 sleep apnea 30.8 SERPINE1 RETN PPARG NOS3 LEP INS
19 acute insulin response 30.8 INS GCG
20 coronary stenosis 30.8 SERPINE1 LPL ADIPOQ
21 sleep disorder 30.8 LEP INS GHRL ADIPOQ
22 kidney disease 30.7 SERPINE1 RETN PPARG NOS3 LEP INS
23 microvascular complications of diabetes 5 30.7 SERPINE1 NOS3 INS IGFBP1
24 anovulation 30.7 LEP INS IGFBP1 GHRL
25 amenorrhea 30.6 LEP INS GHRL
26 non-alcoholic steatohepatitis 30.6 SLC2A4 SERPINE1 PPARG PPARA MTTP MIR122
27 pre-eclampsia 30.6 SERPINE1 NOS3 LEP INS IGFBP1 ADIPOQ
28 chronic kidney disease 30.6 SERPINE1 RETN NOS3 LPL LEP INS
29 cerebrovascular disease 30.6 SERPINE1 RETN MEG3 LPL LEP INS
30 hypertriglyceridemia, familial 30.6 SERPINE1 LPL INS
31 hypothyroidism 30.6 SERPINE1 RETN LPL LEP INS GHRL
32 eating disorder 30.6 LEP GHRL GCG ADIPOQ
33 insulin-like growth factor i 30.6 LEP INS IGFBP1
34 liver cirrhosis 30.5 SLC2A4 RETN MIR122 MEG3 LEP ADIPOQ
35 hypoglycemia 30.5 INS IGFBP1 GHRL GCG
36 apnea, obstructive sleep 30.5 RETN NOS3 LEP INS GHRL GCG
37 hyperthyroidism 30.4 RETN LEP INS GHRL
38 bone resorption disease 30.4 PPARG MIR122 LEP INS
39 hypercholesterolemia, familial, 1 30.4 NOS3 LPL INS
40 hypopituitarism 30.4 LEP INS HSD11B1
41 gestational diabetes 30.4 SLC2A4 RETN PPARG LEP INS IGFBP1
42 peripheral nervous system disease 30.4 NOS3 LEP INS GCG
43 hypolipoproteinemia 30.4 MTTP MIR33A LPL
44 pancreas disease 30.4 MIR33A LEP INS GCG
45 acquired generalized lipodystrophy 30.3 RETN LEP ADIPOQ
46 thyroid gland disease 30.3 PPARG LEP INS
47 arteriosclerosis 30.3 SERPINE1 PPARG PPARA NOS3 LPL INS
48 hyperuricemia 30.3 PPARG LEP INS
49 berardinelli-seip congenital lipodystrophy 30.3 PPARG LEP
50 gastrointestinal system disease 30.2 MIR33A MIR122 GHRL GCG

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

31
# Description HPO Frequency HPO Source Accession
1 hypertension 31 HP:0000822
2 abdominal obesity 31 HP:0012743

Symptoms via clinical synopsis from OMIM:

56
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM:

605552

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.29 ADIPOQ GHRL HSD11B1 INS LEP LPL
2 homeostasis/metabolism MP:0005376 10.21 ADIPOQ GHRL HSD11B1 INS LEP LPL
3 cardiovascular system MP:0005385 10.2 ADIPOQ HSD11B1 INS LEP LPL MTTP
4 growth/size/body region MP:0005378 10.18 ADIPOQ HSD11B1 INS LEP LPL MTTP
5 cellular MP:0005384 10.17 ADIPOQ HSD11B1 IGFBP1 INS LEP LPL
6 immune system MP:0005387 10.1 ADIPOQ HSD11B1 IGFBP1 INS LEP NOS3
7 liver/biliary system MP:0005370 10 ADIPOQ HSD11B1 IGFBP1 INS LEP LPL
8 integument MP:0010771 9.91 ADIPOQ HSD11B1 INS LEP LPL PPARA
9 muscle MP:0005369 9.65 ADIPOQ HSD11B1 INS LEP LPL NOS3
10 renal/urinary system MP:0005367 9.17 ADIPOQ INS LEP NOS3 PPARA PPARG

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

PubMed Health treatment related to Abdominal Obesity-Metabolic Syndrome 1: 62

Healthy lifestyle changes are the first line of treatment for metabolic syndrome . Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking . If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure , high triglycerides , low HDL cholesterol , and high blood sugar . Blood -thinning medicines, such as aspirin , also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome .

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 774)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
4
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
5
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
6
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
7
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
8
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
9
Rufinamide Approved Phase 4 106308-44-5 129228
10
Levetiracetam Approved Phase 4 102767-28-2 441341
11
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
12
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
13
Nitrazepam Approved Phase 4 146-22-5 4506
14
Stiripentol Approved Phase 4 49763-96-4
15
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
16
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
17
Vigabatrin Approved Phase 4 68506-86-5, 60643-86-9 5665
18
Ethosuximide Approved Phase 4 77-67-8 3291
19
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
20
Atorvastatin Approved Phase 4 134523-00-5 60823
21
Fenofibrate Approved Phase 4 49562-28-9 3339
22
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
23
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
24
Galantamine Approved Phase 4 357-70-0 9651
25
Ezetimibe Approved Phase 4 163222-33-1 150311
26
Ramipril Approved Phase 4 87333-19-5 5362129
27
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
28
Pitavastatin Approved Phase 4 147526-32-7, 147511-69-1 6366718 5282452
29
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
30
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
31
Nebivolol Approved, Investigational Phase 4 99200-09-6, 118457-14-0, 152520-56-4 71301
32
Trandolapril Approved Phase 4 87679-37-6 5484727
33
Verapamil Approved Phase 4 52-53-9 2520
34
Haloperidol Approved Phase 4 52-86-8 3559
35
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
36
Atenolol Approved Phase 4 29122-68-7 2249
37
Histamine Approved, Investigational Phase 4 51-45-6 774
38
Nifedipine Approved Phase 4 21829-25-4 4485
39
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
40
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
41
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
42
Liraglutide Approved Phase 4 204656-20-2 44147092
43
Clozapine Approved Phase 4 5786-21-0 2818
44
Bisoprolol Approved Phase 4 66722-44-9 2405
45
Infliximab Approved Phase 4 170277-31-3
46
Glucagon Approved Phase 4 16941-32-5
47
Doxazosin Approved Phase 4 74191-85-8 3157
48
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
49
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
50
Colchicine Approved Phase 4 64-86-8 2833 6167

Interventional clinical trials:

(show top 50) (show all 2831)
# Name Status NCT ID Phase Drugs
1 Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
2 the Long-term Effects of High-doSe pitavaStatin on Diabetogenicity in Comparison With Atorvastatin in Patients With Metabolic Syndrome (LESS-DM) Randomized Clinical Trial Unknown status NCT02940366 Phase 4 Pitavastatin 4 mg orally daily;Atorvastatin 20 mg orally daily
3 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
4 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
5 Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension Unknown status NCT00790946 Phase 4 Valsartan
6 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
7 The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
8 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
9 Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
10 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
11 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
12 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
13 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
14 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
15 Treatment of Coronary Atherosclerosis and Calcification by Insulin Sensitizers in Insulin-Resistant Patients: Evaluated by EBCT, 16-Slice MDCT Coronary Angiography/Scanning, and Intravascular Ultrasound Unknown status NCT00155350 Phase 4 pioglitazone
16 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
17 Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
18 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
19 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
20 A Multicenter, Eight Weeks Treatment, Single Step Titration, Open Label Study Assessing the Percentage of Korean Diabetic Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Dose 10mg, 20mg, 40mg Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
21 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
22 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
23 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
24 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
25 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
26 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4 bromocriptine
27 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
28 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo
29 Comparison of Single and Combination Diuretics in Low-Renin Hypertension Unknown status NCT02351973 Phase 4 Hydrochlorthiazide;Amiloride;Hydrochlorthiazide and Amiloride
30 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
31 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
32 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
33 Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
34 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
35 A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years Unknown status NCT02205931 Phase 4 Antiepileptic drug therapy
36 PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
37 A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
38 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
39 Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
40 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4 fenofibrate;niacin;rosiglitazone
41 A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome) Completed NCT00272311 Phase 4 Aspirin
42 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
43 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome Completed NCT00138528 Phase 4 Fluvastatin
44 The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed NCT00515021 Phase 4 Eplerenone (Morning);Eplerenone (Night-time)
45 The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
46 A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension Completed NCT01138423 Phase 4 Aliskiren;Moxonidine;Hydrochlorothiazide;Placebo (for aliskiren);Placebo (for moxonidine and hydrochlorothiazide)
47 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4 Irbesartan;Hydrochlorothiazide
48 The Effect of Rosiglitazone on Adipocyte-derived Cytokines in Nondiabetics With the Metabolic Syndrome Completed NCT00364221 Phase 4 Rosiglitazone
49 A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
50 A Multicenter, Double Blind, Randomized Study With Two Parallel Groups Comparing The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome Completed NCT00241150 Phase 4 VALSARTAN

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 29 MTTP

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

40
Liver, Endothelial, Heart, Ovary, Prostate, Testes, Bone

Publications for Abdominal Obesity-Metabolic Syndrome 1

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 963)
# Title Authors PMID Year
1
Prospective analysis of the insulin-resistance syndrome (syndrome X). 56 54
1587398 1992
2
Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening. 6
22947299 2012
3
Screening of 336 single-nucleotide polymorphisms in 85 obesity-related genes revealed McKusick-Kaufman syndrome gene variants are associated with metabolic syndrome. 56
19247371 2009
4
Hepatic insulin resistance directly promotes formation of cholesterol gallstones. 56
18587407 2008
5
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. 56
18305138 2008
6
Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. 56
17273170 2007
7
Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. 56
16391564 2006
8
The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. 56
16446448 2006
9
A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. 56
16721486 2006
10
Variants in the ghrelin gene are associated with metabolic syndrome in the Old Order Amish. 6
16204371 2005
11
Association between common polymorphisms of the proopiomelanocortin gene and body fat distribution: a family study. 56
16046320 2005
12
Retinoid x receptor heterodimers in the metabolic syndrome. 56
16093469 2005
13
Association of the metabolic syndrome with intracranial atherosclerotic stroke. 56
16043803 2005
14
Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism. 56
15919835 2005
15
Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. 56
15562396 2004
16
Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. 56
15309680 2004
17
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. 56
14557872 2003
18
Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. 56
12970275 2003
19
Association of polymorphisms in the estrogen receptor alpha gene with body fat distribution. 56
12917706 2003
20
Association of low interleukin-10 levels with the metabolic syndrome in obese women. 56
12629085 2003
21
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. 56
12588201 2003
22
A variation in the ghrelin gene increases weight and decreases insulin secretion in tall, obese children. 6
12161552 2002
23
Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. 6
12050239 2002
24
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. 56
11790215 2002
25
A transgenic model of visceral obesity and the metabolic syndrome. 56
11739957 2001
26
A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. 56
11734540 2001
27
Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. 6
11502844 2001
28
Cardiovascular morbidity and mortality associated with the metabolic syndrome. 56
11315831 2001
29
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. 56
11121050 2000
30
Metabolic implications of body fat distribution. 56
1773700 1991
31
Banting lecture 1988. Role of insulin resistance in human disease. 56
3056758 1988
32
MiR-33 contributes to the regulation of cholesterol homeostasis. 46
20466885 2010
33
Altered body composition in preterm infants at hospital discharge. 61 54
19594474 2009
34
Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. 61 54
18049445 2007
35
[The metabolic syndrome X or insulin resistance syndrome]. 61 54
17304724 2007
36
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. 61 54
16941796 2006
37
New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). 61 54
17119268 2006
38
Expression analysis of genes involved in fat assimilation in human monocytes. 61 54
16801219 2006
39
Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. 54 61
16641887 2006
40
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. 46
16459310 2006
41
Pathophysiology of metabolic syndrome X and its links to the perinatal period. 54 61
15925303 2005
42
The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. 61 54
15505005 2004
43
Infants of diabetic mothers. 61 54
15157588 2004
44
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? 61 54
15025845 2004
45
Metabolic syndrome X: an inflammatory condition? 61 54
14972097 2004
46
Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. 54 61
15104027 2004
47
Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. 61 54
15078145 2004
48
Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. 61 54
14574352 2003
49
The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. 61 54
12946657 2003
50
[Plasma insulin, glucose and lipid levels, and their relations with corrected TIMI frame count in patients with slow coronary flow]. 54 61
12967888 2003

Variations for Abdominal Obesity-Metabolic Syndrome 1

ClinVar genetic disease variations for Abdominal Obesity-Metabolic Syndrome 1:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NOS3 NM_000603.5(NOS3):c.-51-762C>TSNV protective 517660 rs2070744 7:150690079-150690079 7:150992991-150992991
2 GHRL NM_016362.5(GHRL):c.214C>A (p.Leu72Met)SNV Pathogenic,risk factor 5062 rs696217 3:10331457-10331457 3:10289773-10289773
3 GHRL NM_016362.5(GHRL):c.152G>A (p.Arg51Gln)SNV risk factor 5061 rs34911341 3:10331519-10331519 3:10289835-10289835
4 PTS NM_000317.2(PTS):c.(?_-1)_(*1_?)deldeletion Likely pathogenic 375224
5 LMNA NM_170707.4(LMNA):c.1892G>A (p.Gly631Asp)SNV Uncertain significance 66873 rs267607648 1:156108472-156108472 1:156138681-156138681
6 NOS3 NM_000603.5(NOS3):c.774T>C (p.Asp258=)SNV Benign 403248 rs1549758 7:150695726-150695726 7:150998638-150998638
7 NOS3 NM_000603.5(NOS3):c.894T>G (p.Asp298Glu)SNV Benign 14015 rs1799983 7:150696111-150696111 7:150999023-150999023

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 PPARG PPARD PPARA LEP INS GCG
2
Show member pathways
12.77 SLC2A4 PPARG PPARD PPARA LPL LEP
3
Show member pathways
12.66 SLC2A4 RETN LEP INS ADIPOQ
4 12.4 SLC2A4 PPARG INS IGFBP1 GCG ADIPOQ
5
Show member pathways
12.34 SLC2A4 PPARG NOS3 LEP INS ADIPOQ
6
Show member pathways
12.12 LEP INS GHRL GCG
7
Show member pathways
12.08 SLC2A4 NOS3 LEP INS
9
Show member pathways
11.88 SLC2A4 PPARA NOS3 INS
10 11.82 SERPINE1 NOS3 INS
11
Show member pathways
11.76 SLC2A4 INS ADIPOQ
12
Show member pathways
11.72 PPARG PPARD PPARA
13 11.66 PPARG MIR33A LPL INS
14 11.62 SLC2A4 PPARA LEP ADIPOQ
15 11.61 PPARG PPARD PPARA LPL ADIPOQ
16 11.56 SERPINE1 LEP IGFBP1
17 11.44 SLC2A4 SERPINE1 RETN PPARG PPARD PPARA
18 11.41 SLC2A4 PPARG LPL LEP INS ADIPOQ
19 11.21 PPARG PPARD PPARA MIR33A
20 11.1 PPARG LEP ADIPOQ
21 10.99 LEP INS GHRL
22 10.9 SLC2A4 PPARG LEP ADIPOQ
23 10.81 SLC2A4 INS

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Cellular components related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 SERPINE1 RETN LPL LEP INS IGFBP1
2 endoplasmic reticulum lumen GO:0005788 9.35 MTTP INS IGFBP1 GHRL GCG
3 RNA polymerase II transcription factor complex GO:0090575 9.33 PPARG PPARD PPARA
4 extracellular space GO:0005615 9.32 SERPINE1 RETN MIR122 LPL LEP INS

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.02 PPARG PPARD PPARA MTTP LPL LEP
2 fatty acid metabolic process GO:0006631 9.94 PPARG PPARD PPARA LPL
3 positive regulation of cold-induced thermogenesis GO:0120162 9.87 LEP GHRL ADIPOQ
4 wou